{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T12:16:00Z","timestamp":1789474560210,"version":"build-2803163510"},"reference-count":240,"publisher":"Spandidos Publications","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Oncol"],"DOI":"10.3892\/ijo.2022.5302","type":"journal-article","created":{"date-parts":[[2022,1,4]],"date-time":"2022-01-04T11:08:00Z","timestamp":1641294480000},"source":"Crossref","is-referenced-by-count":23,"title":["Retrospective analysis of the preparation and application of immunotherapy in cancer treatment (Review)"],"prefix":"10.3892","volume":"60","author":[{"given":"Jiachen","family":"Lu","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianing","family":"Ding","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoxia","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingtao","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2022,1,4]]},"reference":[{"key":"key20220302121900_b1-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1001\/jamaoncol.2020.2592","article-title":"Benign vs malignant tumors","volume":"6","author":"Patel","year":"2020","journal-title":"JAMA Oncol"},{"key":"key20220302121900_b2-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1182\/blood.2019000568","article-title":"An etiological role for the Epstein-Barr virus in the pathogenesis of classical Hodgkin lymphoma","volume":"134","author":"Murray","year":"2019","journal-title":"Blood"},{"key":"key20220302121900_b3-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1038\/s41575-019-0189-8","article-title":"Global burden of colorectal cancer: Emerging trends, risk factors and prevention strategies","volume":"16","author":"Keum","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"key20220302121900_b4-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.phrs.2017.09.009","article-title":"Modulation of oncogenic transcription factors by bioactive natural products in breast cancer","volume":"128","author":"Hasanpourghadi","year":"2018","journal-title":"Pharmacol Res"},{"key":"key20220302121900_b5-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1001\/jama.2016.4690","article-title":"Pancreatic cyst disease: A review","volume":"315","author":"Stark","year":"2016","journal-title":"JAMA"},{"key":"key20220302121900_b6-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/j.jtho.2016.03.025","article-title":"The IASLC lung cancer staging project: Proposals for coding T categories for subsolid nodules and assessment of tumor size in part-solid tumors in the forthcoming eighth edition of the TNM classification of lung cancer","volume":"11","author":"Travis","year":"2016","journal-title":"J Thorac Oncol"},{"key":"key20220302121900_b7-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"5747","DOI":"10.3390\/ijms21165747","article-title":"In vitro modeling of non-solid tumors: How far can tissue engineering go?","volume":"21","author":"Clara-Trujillo","year":"2020","journal-title":"Int J Mol Sci"},{"key":"key20220302121900_b8-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"172641","DOI":"10.1016\/j.ejphar.2019.172641","article-title":"Hematological malignancies and molecular targeting therapy","volume":"862","author":"Shimada","year":"2019","journal-title":"Eur J Pharmacol"},{"key":"key20220302121900_b9-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1002\/cncr.30371","article-title":"Immunotherapy approaches in the treatment of malignant brain tumors","volume":"123","author":"Dunn-Pirio","year":"2017","journal-title":"Cancer"},{"key":"key20220302121900_b10-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1038\/nrd.2018.169","article-title":"Targeting macrophages: Therapeutic approaches in cancer","volume":"17","author":"Cassetta","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"key20220302121900_b11-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.ejca.2020.09.001","article-title":"Prospective evaluation of the prognostic value of immune-related adverse events in patients with non-melanoma solid tumour treated with PD-1\/PD-L1 inhibitors alone and in combination with radiotherapy","volume":"140","author":"Schweizer","year":"2020","journal-title":"Eur J Cancer"},{"key":"key20220302121900_b12-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1111\/cts.12567","article-title":"Tutorial on monoclonal antibody pharmacokinetics and its considerations in early development","volume":"11","author":"Ovacik","year":"2018","journal-title":"Clin Transl Sci"},{"key":"key20220302121900_b13-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.biologicals.2017.11.001","article-title":"Therapeutic monoclonal antibody N-glycosylation-structure, function and therapeutic potential","volume":"52","author":"Cymer","year":"2018","journal-title":"Biologicals"},{"key":"key20220302121900_b14-ijo-60-02-05302","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1111\/all.13798","article-title":"Legends of allergy\/immunology: Georges K\u00f6hler and the discovery of MONOCLONAL antibodies","volume":"74","author":"Alkan","year":"2019","journal-title":"Allergy"},{"key":"key20220302121900_b15-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.ccell.2017.03.005","article-title":"Eradication of tumors through simultaneous ablation of CD276\/B7H3-positive tumor cells and tumor vasculature","volume":"31","author":"Seaman","year":"2017","journal-title":"Cancer Cell"},{"key":"key20220302121900_b16-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.3390\/cancers12071752","article-title":"Immunotherapy in prostate cancer","volume":"12","author":"Fay","year":"2020","journal-title":"Cancers (Basel)"},{"key":"key20220302121900_b17-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"e1556","DOI":"10.1002\/wnan.1556","article-title":"Antibody and antibody derivatives as cancer therapeutics","volume":"11","author":"Arlotta","year":"2019","journal-title":"Wiley Interdiscip Rev Nanomed Nanobiotechnol"},{"key":"key20220302121900_b18-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.copbio.2019.01.008","article-title":"Selecting and engineering monoclonal antibodies with drug-like specificity","volume":"60","author":"Starr","year":"2019","journal-title":"Curr Opin Biotechnol"},{"key":"key20220302121900_b19-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.sbi.2016.07.012","article-title":"Engineering antibody therapeutics","volume":"38","author":"Chiu","year":"2016","journal-title":"Curr Opin Struct Biol"},{"key":"key20220302121900_b20-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/978-1-62703-586-6_5","article-title":"Polyclonal and monoclonal antibodies in clinic","volume":"1060","author":"Wootla","year":"2014","journal-title":"Methods Mol Biol"},{"key":"key20220302121900_b21-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/256495a0","article-title":"Continuous cultures of fused cells secreting antibody of predefined specificity","volume":"256","author":"K\u00f6hler","year":"1975","journal-title":"Nature"},{"key":"key20220302121900_b22-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1056\/NEJM198203043060906","article-title":"Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody","volume":"306","author":"Miller","year":"1982","journal-title":"N Engl J Med"},{"key":"key20220302121900_b23-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s13238-010-0052-8","article-title":"Monoclonal antibodies-a proven and rapidly expanding therapeutic modality for human diseases","volume":"1","author":"An","year":"2010","journal-title":"Protein Cell"},{"key":"key20220302121900_b24-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.tibtech.2018.05.014","article-title":"The increasingly human and profitable monoclonal antibody market","volume":"37","author":"Grilo","year":"2019","journal-title":"Trends Biotechnol"},{"key":"key20220302121900_b25-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/0958-1669(92)90074-S","article-title":"Antibody expression in bacteriophage systems: The future of monoclonal antibodies?","volume":"3","author":"Garrard","year":"1992","journal-title":"Curr Opin Biotechnol"},{"key":"key20220302121900_b26-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"106639","DOI":"10.1016\/j.intimp.2020.106639","article-title":"Hybridoma technology a versatile method for isolation of monoclonal antibodies, its applicability across species, limitations, advancement and future perspectives","volume":"85","author":"Parray","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"key20220302121900_b27-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/978-3-319-72077-7_2","article-title":"Antibody phage display","volume":"1053","author":"Shim","year":"2017","journal-title":"Adv Exp Med Biol"},{"key":"key20220302121900_b28-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1517\/14712598.5.1.125","article-title":"Applications of ribosome display to antibody drug discovery","volume":"5","author":"Groves","year":"2005","journal-title":"Expert Opin Biol Ther"},{"key":"key20220302121900_b29-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12929-019-0592-z","article-title":"Development of therapeutic antibodies for the treatment of diseases","volume":"27","author":"Lu","year":"2020","journal-title":"J Biomed Sci"},{"key":"key20220302121900_b30-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/s41584-019-0188-8","article-title":"Advances in antibody engineering for rheumatic diseases","volume":"15","author":"Schmid","year":"2019","journal-title":"Nat Rev Rheumatol"},{"key":"key20220302121900_b31-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/978-1-4939-8958-4_9","article-title":"Humanization and simultaneous optimization of monoclonal antibody","volume":"1904","author":"Kuramochi","year":"2019","journal-title":"Methods Mol Biol"},{"key":"key20220302121900_b32-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"5995","DOI":"10.1074\/jbc.RA120.012791","article-title":"Affinity maturation, humanization, and co-crystallization of a rabbit anti-human ROR2 monoclonal antibody for therapeutic applications","volume":"295","author":"Goydel","year":"2020","journal-title":"J Biol Chem"},{"key":"key20220302121900_b33-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/j.chom.2020.04.023","article-title":"Identification of human single-domain antibodies against SARS-CoV-2","volume":"27","author":"Wu","year":"2020","journal-title":"Cell Host Microbe"},{"key":"key20220302121900_b34-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1080\/19420862.2016.1212149","article-title":"Phage display-derived human antibodies in clinical development and therapy","volume":"8","author":"Frenzel","year":"2016","journal-title":"MAbs"},{"key":"key20220302121900_b35-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.3389\/fimmu.2019.01598","article-title":"History of envenoming therapy and current perspectives","volume":"10","author":"Pucca","year":"2019","journal-title":"Front Immunol"},{"key":"key20220302121900_b36-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.imlet.2014.05.010","article-title":"From the discovery of monoclonal antibodies to their therapeutic application: An historical reappraisal","volume":"161","author":"Ribatti","year":"2014","journal-title":"Immunol Lett"},{"key":"key20220302121900_b37-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.addr.2016.11.004","article-title":"The state-of-play and future of antibody therapeutics","volume":"122","author":"Elgundi","year":"2017","journal-title":"Adv Drug Deliv Rev"},{"key":"key20220302121900_b38-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.ejca.2020.01.005","article-title":"Pharmacokinetic\/pharmacodynamic relationship of therapeutic monoclonal antibodies used in oncology: Part 1, monoclonal antibodies, antibody-drug conjugates and bispecific T-cell engagers","volume":"128","author":"Paci","year":"2020","journal-title":"Eur J Cancer"},{"key":"key20220302121900_b39-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"90","DOI":"10.2144\/btn-2019-0054","article-title":"Hybridoma technology: The preferred method for monoclonal antibody generation for in vivo applications","volume":"67","author":"Zaroff","year":"2019","journal-title":"Biotechniques"},{"key":"key20220302121900_b40-ijo-60-02-05302","first-page":"879","article-title":"Human anti-murine immunoglobulin responses in patients receiving monoclonal antibody therapy","volume":"45","author":"Schroff","year":"1985","journal-title":"Cancer Res"},{"key":"key20220302121900_b41-ijo-60-02-05302","first-page":"1723","article-title":"E5 murine monoclonal antiendotoxin antibody in gram-negative sepsis: A randomized controlled trial","volume":"283","author":"Angus","year":"2000","journal-title":"E5 study investigators JAMA"},{"key":"key20220302121900_b42-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1093\/annonc\/mdx768","article-title":"Rituximab: A benchmark in the development of chemotherapy-free treatment strategies for follicular lymphomas","volume":"29","author":"Karmali","year":"2018","journal-title":"Ann Oncol"},{"issue":"Suppl 6","key":"key20220302121900_b43-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"G47","DOI":"10.1016\/j.vaccine.2009.10.124","article-title":"Recent advances in the study of human antibody responses to influenza virus using optimized human hybridoma approaches","volume":"27","author":"Crowe","year":"2009","journal-title":"Vaccine"},{"key":"key20220302121900_b44-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000084184","article-title":"Minimizing the immunogenicity of antibodies for clinical application","volume":"26","author":"Gonzales","year":"2005","journal-title":"Tumour Biol"},{"key":"key20220302121900_b45-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.3389\/fimmu.2020.01986","article-title":"Phage display derived monoclonal antibodies: From bench to bedside","volume":"11","author":"Alfaleh","year":"2020","journal-title":"Front Immunol"},{"key":"key20220302121900_b46-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"4220","DOI":"10.1073\/pnas.86.11.4220","article-title":"Mouse\/human chimeric monoclonal antibody in man: Kinetics and immune response","volume":"86","author":"LoBuglio","year":"1989","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20220302121900_b47-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1056\/NEJM199710093371502","article-title":"A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn.s disease. Crohn.s disease cA2 study group","volume":"337","author":"Targan","year":"1997","journal-title":"N Engl J Med"},{"key":"key20220302121900_b48-ijo-60-02-05302","doi-asserted-by":"crossref","first-page":"3521","DOI":"10.4049\/jimmunol.139.10.3521","article-title":"Production of a mouse-human chimeric monoclonal antibody to CD20 with potent Fc-dependent biologic activity","volume":"139","author":"Liu","year":"1987","journal-title":"J Immunol"},{"key":"key20220302121900_b49-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program","volume":"16","author":"McLaughlin","year":"1998","journal-title":"J Clin Oncol"},{"key":"key20220302121900_b50-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.jacc.2016.05.078","article-title":"1-Year outcomes with intracoronary abciximab in diabetic patients undergoing primary percutaneous coronary intervention","volume":"68","author":"Piccolo","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"key20220302121900_b51-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.ijcard.2016.06.062","article-title":"Management of coronary artery aneurysms using abciximab in children with Kawasaki disease","volume":"220","author":"Bachlava","year":"2016","journal-title":"Int J Cardiol"},{"key":"key20220302121900_b52-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1002\/ajh.25839","article-title":"Prognostic factors and long-term follow-up of basiliximab for steroid-refractory acute graft-versus-host disease: Updated experience from a large-scale study","volume":"95","author":"Liu","year":"2020","journal-title":"Am J Hematol"},{"key":"key20220302121900_b53-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"2334","DOI":"10.1111\/ajt.13739","article-title":"The impact of alemtuzumab and basiliximab induction on patient survival and time to bronchiolitis obliterans syndrome in double lung transplantation recipients","volume":"16","author":"Furuya","year":"2016","journal-title":"Am J Transplant"},{"key":"key20220302121900_b54-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.ejca.2018.06.024","article-title":"First-line mFOLFOX plus cetuximab followed by mFOLFOX plus cetuximab or single-agent cetuximab as maintenance therapy in patients with metastatic colorectal cancer: Phase II randomised MACRO2 TTD study","volume":"101","author":"Aranda","year":"2018","journal-title":"Eur J Cancer"},{"key":"key20220302121900_b55-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/S1470-2045(19)30484-X","article-title":"Palbociclib: A new partner for cetuximab?","volume":"20","author":"Strohbehn","year":"2019","journal-title":"Lancet Oncol"},{"key":"key20220302121900_b56-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1007\/s13238-017-0457-8","article-title":"Current progress in innovative engineered antibodies","volume":"9","author":"Strohl","year":"2018","journal-title":"Protein Cell"},{"key":"key20220302121900_b57-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/j.addr.2006.01.026","article-title":"Engineering of therapeutic antibodies to minimize immunogenicity and optimize function","volume":"58","author":"Presta","year":"2006","journal-title":"Adv Drug Deliv Rev"},{"key":"key20220302121900_b58-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/j.ijbiomac.2019.06.006","article-title":"Phage display antibody libraries: A robust approach for generation of recombinant human monoclonal antibodies","volume":"135","author":"Kumar","year":"2019","journal-title":"Int J Biol Macromol"},{"key":"key20220302121900_b59-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1007\/s13238-019-0639-7","article-title":"Phage display screening of therapeutic peptide for cancer targeting and therapy","volume":"10","author":"Saw","year":"2019","journal-title":"Protein Cell"},{"key":"key20220302121900_b60-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"236","DOI":"10.3390\/toxins10060236","article-title":"Basics of antibody phage display technology","volume":"10","author":"Ledsgaard","year":"2018","journal-title":"Toxins (Basel)"},{"key":"key20220302121900_b61-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/0022-2836(91)90354-9","article-title":"Multiple display of foreign peptides on a filamentous bacteriophage. Peptides from plasmodium falciparum circumsporozoite protein as antigens","volume":"220","author":"Greenwood","year":"1991","journal-title":"J Mol Biol"},{"key":"key20220302121900_b62-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1126\/science.4001944","article-title":"Filamentous fusion phage: Novel expression vectors that display cloned antigens on the virion surface","volume":"228","author":"Smith","year":"1985","journal-title":"Science"},{"key":"key20220302121900_b63-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1126\/science.3823878","article-title":"Chemistry of antibody binding to a protein","volume":"235","author":"Geysen","year":"1987","journal-title":"Science"},{"key":"key20220302121900_b64-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/0378-1119(88)90495-7","article-title":"Antibody-selectable filamentous fd phage vectors: Affinity purification of target genes","volume":"73","author":"Parmley","year":"1988","journal-title":"Gene"},{"key":"key20220302121900_b65-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1126\/science.1696028","article-title":"Searching for peptide ligands with an epitope library","volume":"249","author":"Scott","year":"1990","journal-title":"Science"},{"key":"key20220302121900_b66-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/348552a0","article-title":"Phage antibodies: Filamentous phage displaying antibody variable domains","volume":"348","author":"McCafferty","year":"1990","journal-title":"Nature"},{"key":"key20220302121900_b67-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1002\/biot.201500458","article-title":"Advance in phage display technology for bioanalysis","volume":"11","author":"Tan","year":"2016","journal-title":"Biotechnol J"},{"key":"key20220302121900_b68-ijo-60-02-05302","first-page":"714","article-title":"Advances in the T7 phage display system (Review)","volume":"17","author":"Deng","year":"2018","journal-title":"Mol Med Rep"},{"key":"key20220302121900_b69-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1006\/abio.1996.0241","article-title":"Filamentous phage display of oligopeptide libraries","volume":"238","author":"Burritt","year":"1996","journal-title":"Anal Biochem"},{"key":"key20220302121900_b70-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1038\/nprot.2013.117","article-title":"Isolation of human monoclonal antibodies from peripheral blood B cells","volume":"8","author":"Huang","year":"2013","journal-title":"Nat Protoc"},{"key":"key20220302121900_b71-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"eaax2271","DOI":"10.1126\/sciadv.aax2271","article-title":"An array of 60,000 antibodies for proteome-scale antibody generation and target discovery","volume":"6","author":"Wang","year":"2020","journal-title":"Sci Adv"},{"key":"key20220302121900_b72-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1039\/C6MB00219F","article-title":"Library-based display technologies: Where do we stand?","volume":"12","author":"Gal\u00e1n","year":"2016","journal-title":"Mol Biosyst"},{"key":"key20220302121900_b73-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.3390\/ijms20081861","article-title":"Cognizance of molecular methods for the generation of mutagenic phage display antibody libraries for affinity maturation","volume":"20","author":"Lim","year":"2019","journal-title":"Int J Mol Sci"},{"key":"key20220302121900_b74-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"843","DOI":"10.3390\/molecules25040843","article-title":"Phage display-based nanotechnology applications in cancer immunotherapy","volume":"25","author":"Goracci","year":"2020","journal-title":"Molecules"},{"key":"key20220302121900_b75-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1080\/1061186X.2016.1258570","article-title":"Evolution of phage display technology: From discovery to application","volume":"25","author":"Rahbarnia","year":"2017","journal-title":"J Drug Target"},{"key":"key20220302121900_b76-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"311","DOI":"10.3390\/v10060311","article-title":"Landscape phage: Evolution from phage display to nanobiotechnology","volume":"10","author":"Petrenko","year":"2018","journal-title":"Viruses"},{"key":"key20220302121900_b77-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/0167-5699(96)10025-6","article-title":"Strategies for expressing human antibody repertoires in transgenic mice","volume":"17","author":"Br\u00fcggemann","year":"1996","journal-title":"Immunol Today"},{"key":"key20220302121900_b78-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s00005-014-0322-x","article-title":"Human antibody production in transgenic animals","volume":"63","author":"Br\u00fcggemann","year":"2015","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"key":"key20220302121900_b79-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/978-1-61779-931-0_9","article-title":"Production of human or humanized antibodies in mice","volume":"901","author":"Laffleur","year":"2012","journal-title":"Methods Mol Biol"},{"key":"key20220302121900_b80-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"460","DOI":"10.3389\/fimmu.2018.00460","article-title":"Strategies for generating diverse antibody repertoires using transgenic animals expressing human antibodies","volume":"9","author":"Chen","year":"2018","journal-title":"Front Immunol"},{"key":"key20220302121900_b81-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/0168-9525(85)90089-7","article-title":"Immunoglobulin genes in transgenic mice","volume":"1","author":"Alt","year":"1985","journal-title":"Trends Genet"},{"key":"key20220302121900_b82-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1093\/hmg\/4.6.983","article-title":"Organization of the human immunoglobulin lambda light-chain locus on chromosome 22q11.2","volume":"4","author":"Frippiat","year":"1995","journal-title":"Hum Mol Genet"},{"key":"key20220302121900_b83-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1038\/nbt0796-845","article-title":"High-avidity human IgG kappa monoclonal antibodies from a novel strain of minilocus transgenic mice","volume":"14","author":"Fishwild","year":"1996","journal-title":"Nat Biotechnol"},{"key":"key20220302121900_b84-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1038\/ng0297-146","article-title":"Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice","volume":"15","author":"Mendez","year":"1997","journal-title":"Nat Genet"},{"key":"key20220302121900_b85-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1038\/nbt1135","article-title":"Human antibodies from transgenic animals","volume":"23","author":"Lonberg","year":"2005","journal-title":"Nat Biotechnol"},{"key":"key20220302121900_b86-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1006\/cyto.1995.1003","article-title":"The mouse\/human chimeric monoclonal antibody cA2 neutralizes TNF in vitro and protects transgenic mice from cachexia and TNF lethality in vivo","volume":"7","author":"Siegel","year":"1995","journal-title":"Cytokine"},{"key":"key20220302121900_b87-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1172\/JCI118398","article-title":"Interleukin 6 receptor antibody inhibits muscle atrophy and modulates proteolytic systems in interleukin 6 transgenic mice","volume":"97","author":"Tsujinaka","year":"1996","journal-title":"J Clin Invest"},{"key":"key20220302121900_b88-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1002\/ijc.10647","article-title":"Antiproliferative, antiangiogenic and proapoptotic activity of h-R3: A humanized anti-EGFR antibody","volume":"101","author":"Crombet-Ramos","year":"2002","journal-title":"Int J Cancer"},{"key":"key20220302121900_b89-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1038\/nbt1337","article-title":"From XenoMouse technology to panitumumab, the first fully human antibody product from transgenic mice","volume":"25","author":"Jakobovits","year":"2007","journal-title":"Nat Biotechnol"},{"key":"key20220302121900_b90-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"1846900","DOI":"10.1080\/19420862.2020.1846900","article-title":"Rabbits transgenic for human IgG genes recapitulating rabbit B-cell biology to generate human antibodies of high specificity and affinity","volume":"12","author":"Ros","year":"2020","journal-title":"MAbs"},{"key":"key20220302121900_b91-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1038\/nmeth1001","article-title":"Eukaryotic ribosome display with in situ DNA recovery","volume":"4","author":"He","year":"2007","journal-title":"Nat Methods"},{"key":"key20220302121900_b92-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/978-1-61779-931-0_6","article-title":"Ribosome display","volume":"901","author":"Thom","year":"2012","journal-title":"Methods Mol Biol"},{"key":"key20220302121900_b93-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/978-1-61779-379-0_1","article-title":"Ribosome display: A perspective","volume":"805","author":"Pl\u00fcckthun","year":"2012","journal-title":"Methods Mol Biol"},{"key":"key20220302121900_b94-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1517\/14712598.6.2.177","article-title":"Ribosome display for improved biotherapeutic molecules","volume":"6","author":"Rothe","year":"2006","journal-title":"Expert Opin Biol Ther"},{"key":"key20220302121900_b95-ijo-60-02-05302","first-page":"55","article-title":"Therapeutic antibody engineering and selection strategies","volume":"171","author":"Ministro","year":"2020","journal-title":"Adv Biochem Eng Biotechnol"},{"key":"key20220302121900_b96-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"9022","DOI":"10.1073\/pnas.91.19.9022","article-title":"An in vitro polysome display system for identifying ligands from very large peptide libraries","volume":"91","author":"Mattheakis","year":"1994","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20220302121900_b97-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/jid.2013.521","article-title":"Antibody phage display: Technique and applications","volume":"134","author":"Hammers","year":"2014","journal-title":"J Invest Dermatol"},{"key":"key20220302121900_b98-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1111\/mmi.14187","article-title":"The fascinating biology behind phage display: Filamentous phage assembly","volume":"111","author":"Loh","year":"2019","journal-title":"Mol Microbiol"},{"key":"key20220302121900_b99-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/nmeth1003","article-title":"Ribosome display: Selecting and evolving proteins in vitro that specifically bind to a target","volume":"4","author":"Zahnd","year":"2007","journal-title":"Nat Methods"},{"key":"key20220302121900_b100-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1038\/s41467-020-14705-2","article-title":"In vitro ribosome synthesis and evolution through ribosome display","volume":"11","author":"Hammerling","year":"2020","journal-title":"Nat Commun"},{"key":"key20220302121900_b101-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1586\/14789450.2.3.421","article-title":"Ribosome display: Next-generation display technologies for production of antibodies in vitro","volume":"2","author":"He","year":"2005","journal-title":"Expert Rev Proteomics"},{"key":"key20220302121900_b102-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.nbt.2019.01.004","article-title":"Combination of ribosome display and next generation sequencing as a powerful method for identification of affibody binders against \u03b2-lactamase CTX-M15","volume":"50","author":"Lagoutte","year":"2019","journal-title":"N Biotechnol"},{"key":"key20220302121900_b103-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"118","DOI":"10.3389\/fimmu.2018.00118","article-title":"Next-generation sequencing of antibody display repertoires","volume":"9","author":"Rouet","year":"2018","journal-title":"Front Immunol"},{"key":"key20220302121900_b104-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"e108","DOI":"10.1093\/nar\/gkp514","article-title":"cDNA display: A novel screening method for functional disulfide-rich peptides by solid-phase synthesis and stabilization of mRNA-protein fusions","volume":"37","author":"Yamaguchi","year":"2009","journal-title":"Nucleic Acids Res"},{"key":"key20220302121900_b105-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.jim.2004.04.008","article-title":"In-vitro protein evolution by ribosome display and mRNA display","volume":"290","author":"Lipovsek","year":"2004","journal-title":"J Immunol Methods"},{"key":"key20220302121900_b106-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/978-1-60327-331-2_18","article-title":"Ribosome display with the PURE technology","volume":"607","author":"Ueda","year":"2010","journal-title":"Methods Mol Biol"},{"key":"key20220302121900_b107-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"12297","DOI":"10.1073\/pnas.94.23.12297","article-title":"RNA-peptide fusions for the in vitro selection of peptides and proteins","volume":"94","author":"Roberts","year":"1997","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20220302121900_b108-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1093\/nar\/gnj003","article-title":"Four-base codon mediated mRNA display to construct peptide libraries that contain multiple nonnatural amino acids","volume":"34","author":"Muranaka","year":"2006","journal-title":"Nucleic Acids Res"},{"key":"key20220302121900_b109-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.tibtech.2006.09.004","article-title":"Harnessing phage and ribosome display for antibody optimisation","volume":"24","author":"Dufner","year":"2006","journal-title":"Trends Biotechnol"},{"key":"key20220302121900_b110-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1126\/science.1086907","article-title":"Predominant autoantibody production by early human B cell precursors","volume":"301","author":"Wardemann","year":"2003","journal-title":"Science"},{"key":"key20220302121900_b111-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1038\/nm1080","article-title":"An efficient method to make human monoclonal antibodies from memory B cells: Potent neutralization of SARS coronavirus","volume":"10","author":"Traggiai","year":"2004","journal-title":"Nat Med"},{"key":"key20220302121900_b112-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1016\/j.celrep.2016.04.038","article-title":"A Therapeutic antibody for cancer, derived from single human B cells","volume":"15","author":"Bushey","year":"2016","journal-title":"Cell Rep"},{"key":"key20220302121900_b113-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.nbt.2011.03.014","article-title":"Single B cell antibody technologies","volume":"28","author":"Tiller","year":"2011","journal-title":"N Biotechnol"},{"key":"key20220302121900_b114-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"5288","DOI":"10.1038\/s41467-018-07738-1","article-title":"Single human B cell-derived monoclonal anti-Candida antibodies enhance phagocytosis and protect against disseminated candidiasis","volume":"9","author":"Rudkin","year":"2018","journal-title":"Nat Commun"},{"key":"key20220302121900_b115-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s42003-017-0006-2","article-title":"Recombinant human B cell repertoires enable screening for rare, specific, and natively paired antibodies","volume":"1","author":"Rajan","year":"2018","journal-title":"Commun Biol"},{"key":"key20220302121900_b116-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.vaccine.2009.09.102","article-title":"Long-term presence of memory B-cells specific for different vaccine components","volume":"28","author":"Buisman","year":"2009","journal-title":"Vaccine"},{"key":"key20220302121900_b117-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/0140-6736(90)90050-F","article-title":"Decline of anti-HBs after hepatitis B vaccination and timing of revaccination","volume":"335","author":"Jilg","year":"1990","journal-title":"Lancet"},{"key":"key20220302121900_b118-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1111\/imr.12640","article-title":"Generation of memory B cells and their reactivation","volume":"283","author":"Inoue","year":"2018","journal-title":"Immunol Rev"},{"key":"key20220302121900_b119-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"6127","DOI":"10.1128\/JVI.00347-16","article-title":"Comparison of antibody-dependent cell-mediated cytotoxicity and virus neutralization by HIV-1 Env-specific monoclonal antibodies","volume":"90","author":"von Bredow","year":"2016","journal-title":"J Virol"},{"key":"key20220302121900_b120-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1038\/nprot.2016.102","article-title":"Sequencing and cloning of antigen-specific antibodies from mouse memory B cells","volume":"11","author":"von Boehmer","year":"2016","journal-title":"Nat Protoc"},{"key":"key20220302121900_b121-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"672","DOI":"10.3389\/fmicb.2019.00672","article-title":"Antigen-specific single B cell sorting and monoclonal antibody cloning in guinea pigs","volume":"10","author":"Lei","year":"2019","journal-title":"Front Microbiol"},{"key":"key20220302121900_b122-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.cell.2020.05.025","article-title":"Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients. B cells","volume":"182","author":"Cao","year":"2020","journal-title":"Cell"},{"key":"key20220302121900_b123-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.copbio.2007.10.011","article-title":"Human monoclonal antibodies by immortalization of memory B cells","volume":"18","author":"Lanzavecchia","year":"2007","journal-title":"Curr Opin Biotechnol"},{"key":"key20220302121900_b124-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1084\/jem.20101352","article-title":"Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection","volume":"208","author":"Wrammert","year":"2011","journal-title":"J Exp Med"},{"key":"key20220302121900_b125-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.coph.2018.05.010","article-title":"Monoclonal antibodies as immunomodulatory therapy against cancer and autoimmune diseases","volume":"41","author":"Hafeez","year":"2018","journal-title":"Curr Opin Pharmacol"},{"key":"key20220302121900_b126-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1080\/14712598.2019.1667974","article-title":"iNK-CD64\/16A cells: A promising approach for ADCC?","volume":"19","author":"Walcheck","year":"2019","journal-title":"Expert Opin Biol Ther"},{"key":"key20220302121900_b127-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.3389\/fimmu.2019.01943","article-title":"A tridimensional model for NK cell-mediated ADCC of follicular lymphoma","volume":"10","author":"Decaup","year":"2019","journal-title":"Front Immunol"},{"key":"key20220302121900_b128-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"e130688","DOI":"10.1172\/jci.insight.130688","article-title":"Efficient ADCC killing of meningioma by avelumab and a high-affinity natural killer cell line, haNK","volume":"4","author":"Giles","year":"2019","journal-title":"JCI Insight"},{"key":"key20220302121900_b129-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1080\/14712598.2020.1688298","article-title":"NK cell-based therapeutics for lung cancer","volume":"20","author":"Pockley","year":"2020","journal-title":"Expert Opin Biol Ther"},{"key":"key20220302121900_b130-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1038\/nbt1137","article-title":"Monoclonal antibody therapy of cancer","volume":"23","author":"Adams","year":"2005","journal-title":"Nat Biotechnol"},{"key":"key20220302121900_b131-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1002\/1878-0261.12554","article-title":"FHR4-based immunoconjugates direct complement-dependent cytotoxicity and phagocytosis towards HER2-positive cancer cells","volume":"13","author":"Seguin-Devaux","year":"2019","journal-title":"Mol Oncol"},{"key":"key20220302121900_b132-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1093\/ecco-jcc\/jjw092","article-title":"An overview of the mechanism of action of the monoclonal antibody vedolizumab","volume":"10","author":"Wyant","year":"2016","journal-title":"J Crohns Colitis"},{"key":"key20220302121900_b133-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"540","DOI":"10.3390\/cells8060540","article-title":"Fibroblast growth factor receptor signaling in skin cancers","volume":"8","author":"Czyz","year":"2019","journal-title":"Cells"},{"key":"key20220302121900_b134-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"715","DOI":"10.3390\/cells8070715","article-title":"Fibroblast growth factor receptor functions in glioblastoma","volume":"8","author":"Jimenez-Pascual","year":"2019","journal-title":"Cells"},{"key":"key20220302121900_b135-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.ejphar.2018.07.034","article-title":"Molecular targeted therapy: Treating cancer with specificity","volume":"834","author":"Lee","year":"2018","journal-title":"Eur J Pharmacol"},{"key":"key20220302121900_b136-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/nrc3930","article-title":"Building better monoclonal antibody-based therapeutics","volume":"15","author":"Weiner","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"key20220302121900_b137-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"2949","DOI":"10.1158\/1078-0432.CCR-18-3003","article-title":"FDA approval summary: Pertuzumab for adjuvant treatment of HER2-positive early breast cancer","volume":"25","author":"Howie","year":"2019","journal-title":"Clin Cancer Res"},{"key":"key20220302121900_b138-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1093\/annonc\/mdx106","article-title":"Glioblastoma targeted therapy: Updated approaches from recent biological insights","volume":"28","author":"Touat","year":"2017","journal-title":"Ann Oncol"},{"key":"key20220302121900_b139-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s10555-017-9687-8","article-title":"EGFR-targeted therapies in the post-genomic era","volume":"36","author":"Xu","year":"2017","journal-title":"Cancer Metastasis Rev"},{"key":"key20220302121900_b140-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1080\/14728222.2017.1371137","article-title":"VEGF as a potential target in lung cancer","volume":"21","author":"Frezzetti","year":"2017","journal-title":"Expert Opin Ther Targets"},{"key":"key20220302121900_b141-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/978-3-030-48457-6_9","article-title":"Tenascin-C function in glioma: Immunomodulation and beyond","volume":"1272","author":"Yalcin","year":"2020","journal-title":"Adv Exp Med Biol"},{"key":"key20220302121900_b142-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1186\/s12885-020-07055-1","article-title":"Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: A multicentre, randomised controlled open-label phase II trial","volume":"20","author":"Lieverse","year":"2020","journal-title":"BMC Cancer"},{"key":"key20220302121900_b143-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1053\/j.semnuclmed.2019.02.008","article-title":"PSMA-targeted radiopharmaceuticals for imaging and therapy","volume":"49","author":"Wester","year":"2019","journal-title":"Semin Nucl Med"},{"key":"key20220302121900_b144-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/j.cell.2019.01.021","article-title":"VEGF in signaling and disease: Beyond discovery and development","volume":"176","author":"Apte","year":"2019","journal-title":"Cell"},{"key":"key20220302121900_b145-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/nrc.2016.36","article-title":"Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy","volume":"16","author":"Topalian","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"key20220302121900_b146-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1038\/s41401-018-0062-2","article-title":"Cancer immune checkpoint blockade therapy and its associated autoimmune cardiotoxicity","volume":"39","author":"Zhang","year":"2018","journal-title":"Acta Pharmacol Sin"},{"key":"key20220302121900_b147-ijo-60-02-05302","first-page":"75","article-title":"Role of PD-1 in immunity and diseases","volume":"410","author":"Chamoto","year":"2017","journal-title":"Curr Top Microbiol Immunol"},{"key":"key20220302121900_b148-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s12276-018-0191-1","article-title":"Immune checkpoint inhibitors: Recent progress and potential biomarkers","volume":"50","author":"Darvin","year":"2018","journal-title":"Exp Mol Med"},{"key":"key20220302121900_b149-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"key20220302121900_b150-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1038\/nrc.2017.17","article-title":"Prospects for combining targeted and conventional cancer therapy with immunotherapy","volume":"17","author":"Gotwals","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"key20220302121900_b151-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/j.ccell.2017.05.010","article-title":"SnapShot: Immune checkpoint inhibitors","volume":"31","author":"Abril-Rodriguez","year":"2017","journal-title":"Cancer Cell"},{"key":"key20220302121900_b152-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1182\/blood-2017-06-741033","article-title":"CTLA-4: A moving target in immunotherapy","volume":"131","author":"Rowshanravan","year":"2018","journal-title":"Blood"},{"key":"key20220302121900_b153-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.coi.2017.07.014","article-title":"Lessons from CTLA-4 deficiency and checkpoint inhibition","volume":"49","author":"Lo","year":"2017","journal-title":"Curr Opin Immunol"},{"key":"key20220302121900_b154-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"6363","DOI":"10.1158\/0008-5472.CAN-18-1429","article-title":"Synthetic DNA-encoded monoclonal antibody delivery of anti-CTLA-4 antibodies induces tumor shrinkage in vivo","volume":"78","author":"Duperret","year":"2018","journal-title":"Cancer Res"},{"key":"key20220302121900_b155-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1080\/14737140.2016.1211936","article-title":"Ipilimumab in melanoma","volume":"16","author":"Specenier","year":"2016","journal-title":"Expert Rev Anticancer Ther"},{"key":"key20220302121900_b156-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"2906","DOI":"10.1002\/cncr.31349","article-title":"Immunotherapy and the role of imaging","volume":"124","author":"Carter","year":"2018","journal-title":"Cancer"},{"key":"key20220302121900_b157-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1126\/science.1255904","article-title":"Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4","volume":"345","author":"Kuehn","year":"2014","journal-title":"Science"},{"key":"key20220302121900_b158-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1038\/nm.3746","article-title":"Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations","volume":"20","author":"Schubert","year":"2014","journal-title":"Nat Med"},{"key":"key20220302121900_b159-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1200\/JCO.2017.73.7379","article-title":"Randomized, open-label phase II study evaluating the efficacy and safety of talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone in patients with advanced, unresectable melanoma","volume":"36","author":"Chesney","year":"2018","journal-title":"J Clin Oncol"},{"key":"key20220302121900_b160-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"2056","DOI":"10.1136\/gutjnl-2018-316948","article-title":"Enterocolitis due to immune checkpoint inhibitors: A systematic review","volume":"67","author":"Soularue","year":"2018","journal-title":"Gut"},{"key":"key20220302121900_b161-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.ctrv.2016.02.001","article-title":"Management of toxicities of immune checkpoint inhibitors","volume":"44","author":"Spain","year":"2016","journal-title":"Cancer Treat Rev"},{"key":"key20220302121900_b162-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1186\/s13046-019-1259-z","article-title":"Combination of CTLA-4 and PD-1 blockers for treatment of cancer","volume":"38","author":"Rotte","year":"2019","journal-title":"J Exp Clin Cancer Res"},{"key":"key20220302121900_b163-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N Engl J Med"},{"key":"key20220302121900_b164-ijo-60-02-05302","first-page":"202","article-title":"Immunotherapy: Local chemotherapy synergizes with CTLA-4 inhibition","volume":"15","author":"Sidaway","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"key20220302121900_b165-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.1200\/JCO.2012.41.6750","article-title":"Management of immune-related adverse events and kinetics of response with ipilimumab","volume":"30","author":"Weber","year":"2012","journal-title":"J Clin Oncol"},{"key":"key20220302121900_b166-ijo-60-02-05302","first-page":"727","article-title":"PD-1\/PD-L1 pathway: Current researches in cancer","volume":"10","author":"Han","year":"2020","journal-title":"Am J Cancer Res"},{"key":"key20220302121900_b167-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"561","DOI":"10.3389\/fphar.2017.00561","article-title":"PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: Mechanism, combinations, and clinical outcome","volume":"8","author":"Alsaab","year":"2017","journal-title":"Front Pharmacol"},{"key":"key20220302121900_b168-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1182\/blood-2017-07-740993","article-title":"PD-1 expression and clinical PD-1 blockade in B-cell lymphomas","volume":"131","author":"Xu-Monette","year":"2018","journal-title":"Blood"},{"key":"key20220302121900_b169-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"e1408747","DOI":"10.1080\/2162402X.2017.1408747","article-title":"Blockade of tumor-expressed PD-1 promotes lung cancer growth","volume":"7","author":"Du","year":"2018","journal-title":"Oncoimmunology"},{"key":"key20220302121900_b170-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s12943-018-0864-3","article-title":"Biomarkers for predicting efficacy of PD-1\/PD-L1 inhibitors","volume":"17","author":"Yi","year":"2018","journal-title":"Mol Cancer"},{"key":"key20220302121900_b171-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1093\/annonc\/mdv383","article-title":"Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies","volume":"26","author":"Naidoo","year":"2015","journal-title":"Ann Oncol"},{"key":"key20220302121900_b172-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.coph.2015.05.011","article-title":"PD-1\/PD-L1 inhibitors","volume":"23","author":"Sunshine","year":"2015","journal-title":"Curr Opin Pharmacol"},{"key":"key20220302121900_b173-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.immuni.2018.03.007","article-title":"Combination cancer therapy with immune checkpoint blockade: Mechanisms and strategies","volume":"48","author":"Patel","year":"2018","journal-title":"Immunity"},{"key":"key20220302121900_b174-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1007\/s10147-019-01548-1","article-title":"Combination therapy with PD-1 or PD-L1 inhibitors for cancer","volume":"25","author":"Hayashi","year":"2020","journal-title":"Int J Clin Oncol"},{"key":"key20220302121900_b175-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1158\/1078-0432.CCR-19-3323","article-title":"Targeting PD-1 or PD-L1 in metastatic kidney cancer: Combination therapy in the first-line setting","volume":"26","author":"Aggen","year":"2020","journal-title":"Clin Cancer Res"},{"key":"key20220302121900_b176-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.pharmthera.2018.01.003","article-title":"Combining chemotherapy with PD-1 blockade in NSCLC","volume":"186","author":"Mathew","year":"2018","journal-title":"Pharmacol Ther"},{"issue":"Suppl 15","key":"key20220302121900_b177-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"e15173","DOI":"10.1200\/JCO.2020.38.15_suppl.e15173","article-title":"PD-1 inhibitor combined with radiotherapy and GM-CSF as salvage therapy in patients with chemotherapy-refractory metastatic solid tumors","volume":"38","author":"Kong","year":"2020","journal-title":"J Clin Oncol"},{"key":"key20220302121900_b178-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1093\/annonc\/mdx790","article-title":"Radiotherapy and anti-PD-1\/PD-L1 combinations in lung cancer: Building better translational research platforms","volume":"29","author":"Kordbacheh","year":"2018","journal-title":"Ann Oncol"},{"key":"key20220302121900_b179-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/nrurol.2017.172","article-title":"The anti-PD-1 era-an opportunity to enhance radiotherapy for patients with bladder cancer","volume":"15","author":"Walshaw","year":"2018","journal-title":"Nat Rev Urol"},{"key":"key20220302121900_b180-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"2987","DOI":"10.1200\/JCO.19.00210","article-title":"Axitinib in combination with toripalimab, a humanized immunoglobulin G4 monoclonal antibody against programmed cell death-1, in patients with metastatic mucosal melanoma: An open-label phase IB trial","volume":"37","author":"Sheng","year":"2019","journal-title":"J Clin Oncol"},{"key":"key20220302121900_b181-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"e0212513","DOI":"10.1371\/journal.pone.0212513","article-title":"Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway","volume":"14","author":"Kato","year":"2019","journal-title":"PLoS One"},{"key":"key20220302121900_b182-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/S1470-2045(18)30081-0","article-title":"Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: A non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial","volume":"19","author":"Atkins","year":"2018","journal-title":"Lancet Oncol"},{"key":"key20220302121900_b183-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1158\/1078-0432.CCR-15-2667","article-title":"Molecular pathways: Mechanism of action for talimogene laherparepvec, a new oncolytic virus immunotherapy","volume":"22","author":"Kohlhapp","year":"2016","journal-title":"Clin Cancer Res"},{"key":"key20220302121900_b184-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"2476","DOI":"10.1016\/j.ymthe.2018.07.013","article-title":"Superagonist IL-15-armed oncolytic virus elicits potent antitumor immunity and therapy that are enhanced with PD-1 blockade","volume":"26","author":"Kowalsky","year":"2018","journal-title":"Mol Ther"},{"key":"key20220302121900_b185-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1126\/science.aar7112","article-title":"Personalized vaccines for cancer immunotherapy","volume":"359","author":"Sahin","year":"2018","journal-title":"Science"},{"key":"key20220302121900_b186-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"6984948","DOI":"10.1155\/2018\/6984948","article-title":"Anti-PD-1\/PD-L1 therapy for non-small-cell lung cancer: Toward personalized medicine and combination strategies","volume":"2018","author":"Sui","year":"2018","journal-title":"J Immunol Res"},{"key":"key20220302121900_b187-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1038\/nbt.4195","article-title":"Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo","volume":"36","author":"Rafiq","year":"2018","journal-title":"Nat Biotechnol"},{"key":"key20220302121900_b188-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s13045-019-0831-5","article-title":"Targeting glycosylation of PD-1 to enhance CAR-T cell cytotoxicity","volume":"12","author":"Shi","year":"2019","journal-title":"J Hematol Oncol"},{"key":"key20220302121900_b189-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1097\/PAS.0000000000000590","article-title":"Expression of programmed cell death 1 ligands (PD-L1 and PD-L2) in histiocytic and dendritic cell disorders","volume":"40","author":"Xu","year":"2016","journal-title":"Am J Surg Pathol"},{"issue":"Suppl 1","key":"key20220302121900_b190-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"S31","DOI":"10.1634\/theoncologist.2019-IO-S1-s05","article-title":"PD-1\/PD-L1 blockade therapy in advanced non-small-cell lung cancer: Current status and future directions","volume":"24","author":"Xia","year":"2019","journal-title":"Oncologist"},{"key":"key20220302121900_b191-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1158\/2326-6066.CIR-17-0316","article-title":"PD-L1 binds to B7-1 only in Cis on the same cell surface","volume":"6","author":"Chaudhri","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"key20220302121900_b192-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1158\/1078-0432.CCR-16-1417","article-title":"Atezolizumab: A PD-L1-blocking antibody for bladder cancer","volume":"23","author":"Inman","year":"2017","journal-title":"Clin Cancer Res"},{"key":"key20220302121900_b193-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/S1470-2045(18)30144-X","article-title":"Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): An open-label, single-arm, phase 2 study","volume":"19","author":"Garassino","year":"2018","journal-title":"Lancet Oncol"},{"key":"key20220302121900_b194-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1038\/s41590-018-0257-1","article-title":"LAG-3: A very singular immune checkpoint","volume":"19","author":"Lui","year":"2018","journal-title":"Nat Immunol"},{"key":"key20220302121900_b195-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"e001014","DOI":"10.1136\/jitc-2020-001014","article-title":"LAG-3: From molecular functions to clinical applications","volume":"8","author":"Maruhashi","year":"2020","journal-title":"J Immunother Cancer"},{"key":"key20220302121900_b196-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.immuni.2016.05.001","article-title":"Lag-3, Tim-3, and TIGIT: Co-inhibitory receptors with specialized functions in immune regulation","volume":"44","author":"Anderson","year":"2016","journal-title":"Immunity"},{"key":"key20220302121900_b197-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/imr.12520","article-title":"Tim-3 and its role in regulating anti-tumor immunity","volume":"276","author":"Das","year":"2017","journal-title":"Immunol Rev"},{"key":"key20220302121900_b198-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"e254","DOI":"10.1016\/S1470-2045(16)30030-4","article-title":"Antibody-drug conjugates for cancer therapy","volume":"17","author":"Thomas","year":"2016","journal-title":"Lancet Oncol"},{"key":"key20220302121900_b199-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"e498","DOI":"10.1016\/S1470-2045(15)00007-8","article-title":"Radiation and checkpoint blockade immunotherapy: Radiosensitisation and potential mechanisms of synergy","volume":"16","author":"Sharabi","year":"2015","journal-title":"Lancet Oncol"},{"key":"key20220302121900_b200-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1002\/jcp.28967","article-title":"Potential drugs used in the antibody-drug conjugate (ADC) architecture for cancer therapy","volume":"235","author":"Yaghoubi","year":"2020","journal-title":"J Cell Physiol"},{"key":"key20220302121900_b201-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.biomaterials.2018.04.027","article-title":"Combinational strategy for high-performance cancer chemotherapy","volume":"171","author":"Qin","year":"2018","journal-title":"Biomaterials"},{"key":"key20220302121900_b202-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.canlet.2019.02.048","article-title":"Mechanisms and therapeutic potentials of cancer immunotherapy in combination with radiotherapy and\/or chemotherapy","volume":"452","author":"Yu","year":"2019","journal-title":"Cancer Lett"},{"key":"key20220302121900_b203-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.ejpb.2015.03.018","article-title":"Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy","volume":"93","author":"P\u00e9rez-Herrero","year":"2015","journal-title":"Eur J Pharm Biopharm"},{"key":"key20220302121900_b204-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.ctrv.2019.04.002","article-title":"Management of metastatic bladder cancer","volume":"76","author":"Nadal","year":"2019","journal-title":"Cancer Treat Rev"},{"key":"key20220302121900_b205-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1080\/08830185.2017.1284211","article-title":"Immunotoxins in cancer therapy: Review and update","volume":"36","author":"Akbari","year":"2017","journal-title":"Int Rev Immunol"},{"key":"key20220302121900_b206-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1634\/theoncologist.2014-0358","article-title":"Advances in anticancer immunotoxin therapy","volume":"20","author":"Alewine","year":"2015","journal-title":"Oncologist"},{"key":"key20220302121900_b207-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3390\/biomedicines4020012","article-title":"Plant toxin-based immunotoxins for cancer therapy: A short overview","volume":"4","author":"Polito","year":"2016","journal-title":"Biomedicines"},{"key":"key20220302121900_b208-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.drudis.2015.05.002","article-title":"Immunotoxin therapy for hematologic malignancies: Where are we heading?","volume":"21","author":"Madhumathi","year":"2016","journal-title":"Drug Discov Today"},{"key":"key20220302121900_b209-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3390\/cancers13010086","article-title":"Monoclonal antibody-based immunotherapy and its role in the development of cardiac toxicity","volume":"13","author":"Kumar","year":"2020","journal-title":"Cancers (Basel)"},{"key":"key20220302121900_b210-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1093\/annonc\/mdt405","article-title":"Antibody-based immunotherapy for ovarian cancer: Where are we at?","volume":"25","author":"Tse","year":"2014","journal-title":"Ann Oncol"},{"key":"key20220302121900_b211-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/S0140-6736(19)31774-X","article-title":"Antibody-drug conjugates for cancer","volume":"394","author":"Chau","year":"2019","journal-title":"Lancet"},{"key":"key20220302121900_b212-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1158\/1541-7786.MCR-19-0582","article-title":"Antibody-drug conjugates: A comprehensive review","volume":"18","author":"Khongorzul","year":"2020","journal-title":"Mol Cancer Res"},{"key":"key20220302121900_b213-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s13238-016-0323-0","article-title":"Antibody-drug conjugates: Recent advances in conjugation and linker chemistries","volume":"9","author":"Tsuchikama","year":"2018","journal-title":"Protein Cell"},{"key":"key20220302121900_b214-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"4426","DOI":"10.1158\/0008-5472.CAN-05-4489","article-title":"Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing","volume":"66","author":"Erickson","year":"2006","journal-title":"Cancer Res"},{"key":"key20220302121900_b215-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/sj.mt.6300080","article-title":"Macrophage-mediated bystander effect triggered by tumor cell apoptosis","volume":"15","author":"Huang","year":"2007","journal-title":"Mol Ther"},{"key":"key20220302121900_b216-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1038\/bjc.2017.367","article-title":"Antibody drug conjugates and bystander killing: Is antigen-dependent internalisation required?","volume":"117","author":"Staudacher","year":"2017","journal-title":"Br J Cancer"},{"key":"key20220302121900_b217-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/nrd.2016.268","article-title":"Strategies and challenges for the next generation of antibody-drug conjugates","volume":"16","author":"Beck","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"key20220302121900_b218-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1093\/jnci\/djz035","article-title":"Antibody-drug conjugate-based therapeutics: State of the science","volume":"111","author":"Birrer","year":"2019","journal-title":"J Natl Cancer Inst"},{"key":"key20220302121900_b219-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.pharmthera.2019.04.008","article-title":"Potential mechanisms of target-independent uptake and toxicity of antibody-drug conjugates","volume":"200","author":"Mahalingaiah","year":"2019","journal-title":"Pharmacol Ther"},{"key":"key20220302121900_b220-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1146\/annurev-med-061516-121357","article-title":"Antibody-drug conjugates for cancer treatment","volume":"69","author":"Lambert","year":"2018","journal-title":"Annu Rev Med"},{"key":"key20220302121900_b221-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.ejpb.2019.03.021","article-title":"Antibody-drug conjugates-stability and formulation","volume":"139","author":"Duerr","year":"2019","journal-title":"Eur J Pharm Biopharm"},{"key":"key20220302121900_b222-ijo-60-02-05302","doi-asserted-by":"publisher","DOI":"10.1177\/1758835920962997","article-title":"An overview of antibody-drug conjugates in oncological practice","author":"Theocharopoulos","year":"2020","journal-title":"Ther Adv Med Oncol"},{"key":"key20220302121900_b223-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"5628","DOI":"10.1002\/jcp.27419","article-title":"Antibody-drug conjugates (ADCs) for cancer therapy: Strategies, challenges, and successes","volume":"234","author":"Abdollahpour-Alitappeh","year":"2019","journal-title":"J Cell Physiol"},{"key":"key20220302121900_b224-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s13238-017-0408-4","article-title":"Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins","volume":"9","author":"Liu","year":"2018","journal-title":"Protein Cell"},{"key":"key20220302121900_b225-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s13045-019-0786-6","article-title":"Antibody-drug conjugates in clinical trials for lymphoid malignancies and multiple myeloma","volume":"12","author":"Yu","year":"2019","journal-title":"J Hematol Oncol"},{"key":"key20220302121900_b226-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.pharmthera.2016.07.012","article-title":"Antibody-drug conjugates: Current status and future perspectives","volume":"167","author":"G\u00e9bleux","year":"2016","journal-title":"Pharmacol Ther"},{"key":"key20220302121900_b227-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1146\/annurev-bioeng-071114-040733","article-title":"Advances in antibody design","volume":"17","author":"Tiller","year":"2015","journal-title":"Annu Rev Biomed Eng"},{"key":"key20220302121900_b228-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"5510","DOI":"10.3390\/ijms21155510","article-title":"Antibody-drug conjugates: The new frontier of chemotherapy","volume":"21","author":"Ponziani","year":"2020","journal-title":"Int J Mol Sci"},{"key":"key20220302121900_b229-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1021\/acs.accounts.9b00273","article-title":"Near-infrared photoimmunotherapy of cancer","volume":"52","author":"Kobayashi","year":"2019","journal-title":"Acc Chem Res"},{"key":"key20220302121900_b230-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1097\/DSS.0000000000000800","article-title":"Photodynamic therapy: A clinical consensus guide","volume":"42","author":"Ozog","year":"2016","journal-title":"Dermatol Surg"},{"key":"key20220302121900_b231-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"163","DOI":"10.3390\/ph12040163","article-title":"Fighting hypoxia to improve PDT","volume":"12","author":"Larue","year":"2019","journal-title":"Pharmaceuticals (Basel)"},{"key":"key20220302121900_b232-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1158\/1541-7786.MCR-17-0333","article-title":"Syngeneic mouse models of oral cancer are effectively targeted by anti-CD44-Based NIR-PIT","volume":"15","author":"Nagaya","year":"2017","journal-title":"Mol Cancer Res"},{"key":"key20220302121900_b233-ijo-60-02-05302","first-page":"4380","article-title":"Ability of specific monoclonal antibodies and conventional antisera conjugated to hematoporphyrin to label and kill selected cell lines subsequent to light activation","volume":"45","author":"Mew","year":"1985","journal-title":"Cancer Res"},{"key":"key20220302121900_b234-ijo-60-02-05302","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.4049\/jimmunol.130.3.1473","article-title":"Photoimmunotherapy: Treatment of animal tumors with tumor-specific monoclonal antibody-hematoporphyrin conjugates","volume":"130","author":"Mew","year":"1983","journal-title":"J Immunol"},{"key":"key20220302121900_b235-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"2218","DOI":"10.7150\/thno.53056","article-title":"Cancer photo-immunotherapy: From bench to bedside","volume":"11","author":"Wang","year":"2021","journal-title":"Theranostics"},{"key":"key20220302121900_b236-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1038\/nm.2554","article-title":"Cancer cell-selective in vivo near infrared photoimmunotherapy targeting specific membrane molecules","volume":"17","author":"Mitsunaga","year":"2011","journal-title":"Nat Med"},{"key":"key20220302121900_b237-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"102632","DOI":"10.1016\/j.ebiom.2020.102632","article-title":"Near infrared photoimmunotherapy targeting DLL3 for small cell lung cancer","volume":"52","author":"Isobe","year":"2020","journal-title":"EBioMedicine"},{"key":"key20220302121900_b238-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1007\/s10120-019-00988-y","article-title":"Cancer neovasculature-targeted near-infrared photoimmunotherapy (NIR-PIT) for gastric cancer: Different mechanisms of phototoxicity compared to cell membrane-targeted NIR-PIT","volume":"23","author":"Nishimura","year":"2020","journal-title":"Gastric Cancer"},{"key":"key20220302121900_b239-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/s41586-020-2168-1","article-title":"Multispecific drugs herald a new era of biopharmaceutical innovation","volume":"580","author":"Deshaies","year":"2020","journal-title":"Nature"},{"key":"key20220302121900_b240-ijo-60-02-05302","doi-asserted-by":"publisher","first-page":"1703531","DOI":"10.1080\/19420862.2019.1703531","article-title":"Antibodies to watch in 2020","volume":"12","author":"Kaplon","year":"2020","journal-title":"MAbs"}],"container-title":["International Journal of Oncology"],"original-title":[],"deposited":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T08:39:51Z","timestamp":1700037591000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ijo.2022.5302"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,4]]},"references-count":240,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,1,4]]}},"URL":"https:\/\/doi.org\/10.3892\/ijo.2022.5302","relation":{},"ISSN":["1019-6439","1791-2423"],"issn-type":[{"value":"1019-6439","type":"print"},{"value":"1791-2423","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,4]]},"article-number":"12"}}